Search company, investor...


Founded Year



Grant - IV | Alive

Total Raised


Last Raised

$5.1M | 1 yr ago

About Humanetics

Humanetics is a clinical-stage pharmaceutical company engaged in developing and commercializing products to enhance human health and wellbeing in markets with urgent and unmet needs. It has a focus on radiation modulators for oncology, medical imaging, and medical countermeasure uses. The company develops BIO 300, a highly selective modulator of inflammation, cell cycle arrest, and DNA damage repair. Humanetics was founded in 1988 and is based in Minneapolis, Minnesota.

Headquarters Location

7760 France Avenue South, Suite 920

Minneapolis, Minnesota, 55435,

United States


Missing: Humanetics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Humanetics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Humanetics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Humanetics is included in 2 Expert Collections, including Cancer.



4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Humanetics Patents

Humanetics has filed 35 patents.

The 3 most popular patent topics include:

  • Radiation health effects
  • Radiobiology
  • Dosage forms
patents chart

Application Date

Grant Date


Related Topics




Sensors, Automotive safety technologies, Vehicle braking technologies, Spaceplanes, Mechanical power control


Application Date


Grant Date



Related Topics

Sensors, Automotive safety technologies, Vehicle braking technologies, Spaceplanes, Mechanical power control



Latest Humanetics News

Humanetics Rolls out New Customer Service Centers of Excellence Across Europe

May 24, 2023

FARMINGTON HILLS, Mich.--(BUSINESS WIRE)--As part of Humanetics’ commitment to deliver the best customer service, and to integrate its expertise across its global network, today the company announced the formation of four customer service hubs in Europe. Each “integrated” hub will focus on a different aspect of developing and maintaining a fleet of crash test dummies– known in the automotive industry as Anthropomorphic Test Devices (ATDs) – and active safety devices both of which are used by au

Humanetics Frequently Asked Questions (FAQ)

  • When was Humanetics founded?

    Humanetics was founded in 1988.

  • Where is Humanetics's headquarters?

    Humanetics's headquarters is located at 7760 France Avenue South, Suite 920, Minneapolis.

  • What is Humanetics's latest funding round?

    Humanetics's latest funding round is Grant - IV.

  • How much did Humanetics raise?

    Humanetics raised a total of $5.74M.

  • Who are the investors of Humanetics?

    Investors of Humanetics include U.S. Department of Defense, National Institute of Allergy and Infectious Diseases, NASA and RAIN Source Capital.

  • Who are Humanetics's competitors?

    Competitors of Humanetics include Bellus Health, Arena Pharmaceuticals, CytImmune Sciences, Aquinox Pharmaceuticals, Stemina Biomarker Discovery, Symphogen, Embera NeuroTherapeutics, Vasopharm, CoImmune, Profectus BioSciences and 65 more.

Compare Humanetics to Competitors

Intarcia Therapeutics

Intarcia Therapeutics is a biopharmaceutical company based in Boston, Massachusetts. Intarcia is engaged in the development of a pipeline of products for the proprietary Medici Drug Delivery System comprised of three technologies: A stabilization technology that allows for proteins, peptides, antibody fragments, and other highly potent small molecules to be stabilized at or above human body temperatures, a matchstick-sized osmotic mini-pump that is placed under the dermal layer of skin to deliver a continuous and consistent flow of medication, and a placement technology including proprietary tools designed to provide an optimal user experience.

Neuraltus Pharmaceuticals

Neuraltus Pharmaceuticals is a privately-held biopharmaceutical company dedicated to developing and commercializing innovative therapeutics that address critical unmet needs for patients and physicians in the treatment of neurodegenerative diseases. The Company is collaborating with global ALS specialists and seeking input from patient advocacy organizations to help inform the clinical development path and better understand the needs of people affected by the disease.

CoImmune Logo

CoImmune, fka Argos Therapeutics, is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases. Using biological components from each patient, the company's immunotherapies employ the patient's dendritic cells to activate an immune response specific to the patient's disease.

Actinobac Biomed

Actinobac Biomed is a biopharmaceutical company developing therapeutics for multiple indications, including blood cancers, autoimmune/inflammatory diseases, and HIV. Its drug candidates are based upon Leukothera (LtxA), a natural protein that targets and eliminates white blood cells (WBCs) involved in the mechanism of many diseases. Products based upon Leukothera are being developed by Actinobac for the treatment of leukemia/lymphoma, dry eye, and psoriasis.

NeuroMolecular Pharmaceuticals

NeuroMolecular Pharmaceuticals is developing and commercializing superior neuroprotective medicines for the treatment of central nervous system (CNS) disorders. The Company has built a robust pipeline of neuropsychiatric products based upon its scientists' unique understanding of glutamate's central role in mediating CNS disorders. NeuroMolecular is rapidly advancing its next-generation medicines into clinical studies, with preclinical programs underway in depression, pain, Alzheimer's disease, Parkinson's disease, multiple sclerosis and epilepsy. NeuroMolecular is initially focusing on the development of superior derivatives and dosage formulations of memantine, a drug recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer's disease.

NeoCytex BioPharma

NeoCytex BioPharmaceuticals develops therapeutics to promote the repair and rejuvenation of damaged tissues. The lead drug candidate NBI-18 is being developed for speeding up recovery from neurodegenerative (Parkinson's, Alzheimer's) and cerebrovascular diseases.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.